Zobrazeno 1 - 10
of 114
pro vyhledávání: '"Ai-Min Hui"'
Autor:
Qiao Li, Ying Cheng, Zhongsheng Tong, Yunjiang Liu, Xian Wang, Min Yan, Jianhua Chang, Shusen Wang, Caiwen Du, Liang Li, Chunjiao Wu, Mingxia Wang, Zhuo Wang, Zhuli Wu, Xingli Wang, Yongli Jin, Lei Diao, Yi Sun, Yongjiao Zhang, Ai-Min Hui, Binghe Xu
Publikováno v:
Nature Communications, Vol 15, Iss 1, Pp 1-10 (2024)
Abstract Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion (phase 1b) phase 1 tri
Externí odkaz:
https://doaj.org/article/a970daa7143b4f0c9d62cb86b63129d8
Autor:
Huiling Qin, Yan Tan, Lei Diao, Ai-Min Hui, Zhuli Wu, Yongchun Zhou, Juan Sun, Xiao Xiang, Jingjun Qiu, Wei Hu
Publikováno v:
Drugs in R&D, Vol 23, Iss 4, Pp 465-473 (2023)
Abstract Background and Objectives This study was conducted to investigate the effect of high-fat meals on the pharmacokinetics (PK) and safety profile of SAF-189s, a novel ALK/ROS1 inhibitor. Methods This was a single-center, phase I, open-label, cr
Externí odkaz:
https://doaj.org/article/a513998392c64eec8b24dd33ea1d2764
Autor:
Xiaojie Hu, Wenbin Li, Kang Zeng, Zhongyuan Xu, Changxing Li, Zhuang Kang, Shenglan Li, Xin Huang, Pu Han, Hongmei Lin, Ai-Min Hui, Yan Tan, Lei Diao, Ben Li, Xingli Wang, Zhuli Wu, Xiaoxi Lin
Publikováno v:
BMC Medicine, Vol 21, Iss 1, Pp 1-10 (2023)
Abstract Background Surgery is a common treatment strategy for patients with neurofibromatosis type 1 (NF1)-related plexiform neurofibroma (PN) and has limited efficacy. FCN-159 is a novel anti-tumorigenic drug via selective inhibition of MEK1/2. Thi
Externí odkaz:
https://doaj.org/article/40e19bb09d2a4f40ac6a436eed7cad1e
Autor:
Gang Yuan, Yili Chen, Li Li, Xin Wang, Gang Wei, Jiawei Zeng, Ai-Min Hui, Yueyun Jiang, Han Zhao, Lei Diao, Yongchun Zhou, Yinglian Xiao, Minhu Chen
Publikováno v:
International Journal of Clinical Practice, Vol 2024 (2024)
Background. Tenapanor is a locally acting selective sodium-hydrogen exchanger 3 inhibitor with the potential to treat sodium/phosphorus and fluid overload in various cardiac-renal diseases, which has been approved for constipation-predominant irritab
Externí odkaz:
https://doaj.org/article/d85dbf56ed6043709878e54acef2fe34
Autor:
Ai-Min Hui, Jingxin Li, Li Zhu, Rong Tang, Huayue Ye, Mei Lin, Lei Ge, Xiyuan Wang, Fuzhong Peng, Zhenggang Wu, Xiling Guo, Yunfeng Shi, Hongxing Pan, Jiahong Zhu, Zhizhou Song, Jingjun Qiu, Wei Wang, Jianfei Zheng, Orkun Ozhelvaci, Svetlana Shpyro, Meghan Bushway, Evelyna Derhovanessian, Marie-Cristine Kühnle, Ulrich Luxemburger, Alexander Muik, Yoana Shishkova, Zakaria Khondker, Simin Hu, Eleni Lagkadinou, Uğur Şahin, Özlem Türeci, Fengcai Zhu
Publikováno v:
The Lancet Regional Health. Western Pacific, Vol 29, Iss , Pp 100586- (2022)
Summary: Background: BNT162b2, an mRNA vaccine against COVID-19, is being utilised worldwide, but immunogenicity and safety data in Chinese individuals are limited. Methods: This phase 2, randomised, double-blind, placebo-controlled trial included he
Externí odkaz:
https://doaj.org/article/0308eea312194f20ae6eecf0dc7517c4
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 15 (2022)
Introduction: Few data have been published on the ethnic sensitivity of effectiveness, pharmacokinetics (PK), and pharmacodynamics (PD) of avatrombopag for the management of thrombocytopenia in patients with chronic liver disease (CLD). Methods: An e
Externí odkaz:
https://doaj.org/article/e79ac3d5944546308d1d8de72d981930
Publikováno v:
Life, Vol 12, Iss 8, p 1254 (2022)
mRNA vaccines have been revolutionary in combating the COVID-19 pandemic in the past two years. They have also become a versatile tool for the prevention of infectious diseases and treatment of cancers. For effective vaccination, mRNA formulation, de
Externí odkaz:
https://doaj.org/article/cf595457cca8420585761e64b0ed9d39
Autor:
Jiangfan Li, Yan Tan, Kexin Li, Ai-Min Hui, Zhuli Wu, Pu Han, Zhen Wei, Jingjun Qiu, Lei Diao, Xuhong Wang
Publikováno v:
Advances in Therapy. 40:1074-1086
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::112f6502cf468b92c9cff485142b78b9
https://doi.org/10.1007/s12325-022-02375-z
https://doi.org/10.1007/s12325-022-02375-z
Autor:
Lili Mao, Jun Guo, Lingjun Zhu, Yu Jiang, Wangjun Yan, Jian Zhang, Ai-Min Hui, Yuchen Yang, Lei Diao, Yan Tan, Han Zhao, Yiqian Jiang, Zhuli Wu, Lu Si
Publikováno v:
European Journal of Cancer. 175:125-135
A phase 1a first-in-human study evaluated the safety/tolerability, preliminary antitumour activity and pharmacokinetics of the oral MEK1/2 inhibitor FCN-159 in Chinese patients with advanced, NRAS-mutant melanoma.Patients received a single FCN-159 do
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5d33e78cf8fd6b88cd32969cddfa75c
https://doi.org/10.1016/j.ejca.2022.08.005
https://doi.org/10.1016/j.ejca.2022.08.005
Autor:
Lin, Lin, Hongming, Pan, Xingya, Li, Chengling, Zhao, Jiangtao, Sun, Xingsheng, Hu, Yiping, Zhang, Mengzhao, Wang, Xiubao, Ren, Xiaoyong, Luo, Guoyong, Shan, Ai-Min, Hui, Zhuli, Wu, Huilong, Liu, Ling, Tian, Yuankai, Shi
Publikováno v:
Lung Cancer. 166:98-106
There are no approved epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for EGFR-mutated non-small cell lung cancer (NSCLC) without EGFR T790M mutation after progression on first- or second-generation EGFR-TKIs.We conducted th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0289af09846c03d0be9800a25dc944bf
https://doi.org/10.1016/j.lungcan.2022.01.025
https://doi.org/10.1016/j.lungcan.2022.01.025